Perth, Oct 24, 2007 AEST (ABN Newswire) - HELICON GROUP LIMITED (ASX: HCG) announced today the relocation of its CEO, Mr Peter Abrahamson to Shanghai to oversee the implementation of its China Strategy.
"Locating our key executive to be close to our customers and partners is critically important to the success of our plans" commented Helicon's Chairman, Dr Saliba Sassine.
"Mr Abrahamson is a highly experienced international executive. He has a proven track record in Asia with his previous roles heading Allergan's and AMO's operations in Asia covering nine countries, including China," said Dr Sassine. "Mr Abrahamson is returning to familiar ground and exciting challenges."
Helicon is a specialty pharmaceutical company that licenses proven proprietary products and drives their market value growth in China, the world's fastest growing pharmaceutical market. The company already owns the rights to three such products which are at various stages of the regulatory process. Helicon is also actively seeking to add to its portfolio and is negotiating with various groups for the rights to the China and other North Asian markets.
"Being on the ground in China is really the best way to build Helicon' franchise and I am looking forward to returning to this dynamic part of the world to drive the growth of our business" commented Peter Abrahamson.
Contact
Peter Abrahamson
Helicon Group Limited
Tel: +61 411 336 330
Email: peter@helicongroup.com.au
Website: www.helicongroup.com.au
| ||
|
